1868 related articles for article (PubMed ID: 17407649)
1. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
4. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
5. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
6. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
9. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
10. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
Cohen A; Horton ES
Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
[TBL] [Abstract][Full Text] [Related]
11. DPP-4 inhibitors.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):517-33. PubMed ID: 18054733
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
13. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
18. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Davidson JA; Parente EB; Gross JL
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
[TBL] [Abstract][Full Text] [Related]
19. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
20. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
